- Previous Close
0.1000 - Open
0.1000 - Bid 0.1000 x --
- Ask 0.1050 x --
- Day's Range
0.1000 - 0.1020 - 52 Week Range
0.0910 - 0.2100 - Volume
635,960 - Avg. Volume
1,562,704 - Market Cap (intraday)
120.755M - Beta (5Y Monthly) 0.00
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date Feb 27, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
0.33
Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer in Australia and internationally. The company product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer; and IL-12-TM for treating solid tumors. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is based in Preston, Australia.
www.arovella.comRecent News: ALA.AX
View More
Performance Overview: ALA.AX
Trailing total returns as of 3/14/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALA.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALA.AX
View MoreValuation Measures
Market Cap
118.39M
Enterprise Value
106.64M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
704.72
Price/Book (mrq)
10.26
Enterprise Value/Revenue
737.96
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-181.62%
Return on Assets (ttm)
-45.61%
Return on Equity (ttm)
-85.35%
Revenue (ttm)
3.45M
Net Income Avi to Common (ttm)
-6.26M
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
11.75M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-4.6M
Research Analysis: ALA.AX
View MoreCompany Insights: ALA.AX
ALA.AX does not have Company Insights